Ligand Pharmaceuticals (Nasdaq: LGND) announced it will report its second quarter 2026 financial results on Thursday, August 6, 2026, followed by a conference call at 8:30 a.m. Eastern time to discuss results and provide a general business update.
The call offers U.S. local and toll-free dial-in options, international access via global dial-in numbers using Meeting ID 780702347, and a live and replay webcast. Ligand describes itself as a royalty aggregator with economic interests in more than 200 development and commercial-stage biopharmaceutical assets and also licenses its Captisol and NITRICIL technologies.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – LGND
-0.69%
-0.69%Session close to close
In the Jul 23 session, LGND declined 0.69%, reflecting a mild negative market reaction.
LGND's earnings-date history recorded -0.06% and -2.32% reactions. That platform record places this ...
Analysis
LGND's earnings-date history recorded -0.06% and -2.32% reactions. That platform record places this scheduling notice alongside prior pre-results announcements; recent insider data showed Net Selling, while the August 6 report remains the key watchpoint.
Scheduled fourth-quarter and full-year 2025 results with an 8:30 a.m. call.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Both prior earnings-date announcements were followed by negative 24-hour reactions: -0.06% and -2.32%.
Key Terms
royalty aggregator, late-stage clinical development programs
2 terms
royalty aggregatorfinancial
"Ligand is a leading royalty aggregator, partnering with biopharmaceutical companies"
A royalty aggregator is a company or fund that buys and manages many royalty or revenue-sharing rights across industries, such as music, pharmaceuticals, natural resources, or intellectual property. Like a person buying a collection of toll booths instead of running a highway, it pools small, ongoing payments from many sources into a single portfolio, creating diversified, often predictable cash flows that investors can track and value.
late-stage clinical development programsmedical
"partnering with biopharmaceutical companies to finance and advance late-stage clinical development programs"
Programs composed of the final, large-scale clinical trials and supporting studies that test a drug or medical device’s safety, effectiveness, dosing, and manufacturing before regulatory approval. These are the decisive “final road tests” for a treatment, often including pivotal Phase IIb/III studies and activities needed for filings. Results and timelines from late-stage programs strongly influence a developer’s chances of approval and the timing of potential commercial value, which is why they matter to investors.
JUPITER, Fla., July 23, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report second quarter 2026 financial results on Thursday, August 6, 2026. The company will hold a conference call beginning at 8:30 a.m. Eastern time to discuss the results and provide a general business update.
Live and replay webcasts of the call are available here.
About Ligand Ligand is a leading royalty aggregator, partnering with biopharmaceutical companies to finance and advance late-stage clinical development programs. Ligand owns and manages one of the largest and most diversified portfolios of biopharmaceutical royalties in the industry, with economic interests in more than 200 development and commercial-stage assets. Ligand funds high-value programs in exchange for long-term economic interests, aligning capital with clinical and commercial success. Ligand’s royalty portfolio is designed to deliver consistent and predictable revenue streams across a broad range of therapeutic assets. Ligand also licenses its proprietary technologies, Captisol® and NITRICIL™, to support drug development and formulation across its global partner network. For more information, visit www.ligand.com or follow Ligand on X and LinkedIn.
When will Ligand (Nasdaq: LGND) report its second quarter 2026 earnings?
Ligand plans to report its second quarter 2026 financial results on Thursday, August 6, 2026. According to Ligand, the release will be accompanied by a conference call and webcast discussing the results and providing a general business update for investors and analysts.
What time is Ligand's Q2 2026 earnings conference call on August 6, 2026?
Ligand’s Q2 2026 earnings conference call starts at 8:30 a.m. Eastern time on August 6, 2026. According to Ligand, the call will review quarterly financial results and include a general business update accessible by phone and webcast.
How can investors access the Ligand (LGND) Q2 2026 earnings call and webcast?
Investors can join by phone using U.S. local +1 (585) 542-9983, U.S. toll-free +1 (833) 461-5787, or international global dial-in numbers with Meeting ID 780702347. According to Ligand, a live and replay webcast will also be available online.
What is the Meeting ID for Ligand's August 6, 2026 Q2 2026 earnings call?
The Meeting ID for Ligand’s second quarter 2026 earnings conference call is 780702347. According to Ligand, participants can use this ID when dialing in via global international numbers to access the call and follow the company’s financial discussion.
What type of business does Ligand (LGND) describe ahead of its Q2 2026 results?
Ligand describes itself as a royalty aggregator focused on financing late-stage biopharmaceutical programs. According to Ligand, it holds economic interests in over 200 development and commercial-stage assets and licenses proprietary technologies Captisol and NITRICIL to partners worldwide.
Will a replay of Ligand's August 6, 2026 Q2 2026 earnings webcast be available?
Yes, Ligand states that both a live and replay webcast of the August 6, 2026 Q2 2026 earnings call will be available. According to Ligand, investors can access the replay online after the event for additional review.
